ENDRA Life Sciences Inc.
NDRA
$3.45
-$0.21-5.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 75.02% | -76.25% | -5.60% | 19.69% | -90.18% |
| Total Depreciation and Amortization | -1.72% | -14.07% | 7.78% | -10.05% | -8.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -113.70% | 171.89% | 1,701.65% | -89.66% | 13.42% |
| Change in Net Operating Assets | -89.06% | 191.42% | -589.19% | -55.76% | 108.97% |
| Cash from Operations | 14.69% | 8.54% | 20.45% | 2.84% | 1.39% |
| Capital Expenditure | -- | -- | -100.00% | 140.74% | -291.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -65.22% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -100.00% | 146.22% | -1,134.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -- | -- | -- | 1,375.33% | -24.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -99.98% | 1,465.00% | -71.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.16% | 8.44% | -131.44% | 409.91% | -239.43% |